Barclays raised the firm’s price target on Qiagen (QGEN) to $58 from $55 and keeps an Overweight rating on the shares. The company’s guide implies a “steep ramp” in sales and margins, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN: